During the 2020 OncLive®
State of the Science Summit™
on Breast Cancer, we asked experts from Virginia Cancer Specialists, Georgetown University, Dana-Farber Cancer Institute, and Johns Hopkins Medicine to provide insight on some of the pivotal research being conducted at their respective institutions.
Neelima Denduluri, MD: Associate Chair of Breast Medical Oncology and Medical Oncologist, Virginia Cancer Specialists, US Oncology Network
Neelima Denduluri, MD
“One trial that we’re very excited about is speaking to the theme of hormone receptor (HR)–positive, HER2-negative early breast cancer. While we know that endocrine therapy certainly improves outcomes, as does chemotherapy in selected populations, we still have room to improve. CDK4/6 inhibitors have really moved the field forward in stage IV breast cancer, and we really need to see how that translates into the early breast cancer setting.
... to read the full story